Steven Cohen Neurocrine Biosciences Inc Call Options Transaction History

Point72 Asset Management, L.P.

  • $36.6 Billion
  • Q3 2024

Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$75.79 - $100.07 $6 Million - $7.93 Million
79,200 Added 79.2%
179,200 $17.5 Million
Q2 2018

Aug 14, 2018
BUY
$75.3 - $105.99 $7.53 Million - $10.6 Million
100,000 New
100,000 $9.82 Million

Others Institutions Holding NBIX

# of Institutions
623
Shares Held
94.2M
Call Options Held
632K
Put Options Held
621K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email